Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Outubro 2023 - 5:30PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines, today
announced that, effective on October 16th, 2023, the company
granted a stock option to purchase an aggregate of 32,800 shares of
common stock to 1 new employee, as a material inducement to their
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option that was granted has an exercise price of $4.00
per share, which is equal to the closing price of Stoke’s common
stock on October 16th, 2023. The option will vest over a 4-year
period, with 1/4th of the shares underlying the employee’s option
vesting on the one-year anniversary of the applicable vesting
commencement date and the remaining shares thereafter vesting
monthly at a rate of 1/48th of the shares underlying the employee’s
option over the following 36 months, subject to the employee’s
continued employment with Stoke on such vesting dates. The option
has a term of 10 years and is subject to the terms and conditions
of the 2023 Inducement Plan and the stock option agreement covering
the grant.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to addressing the underlying cause of severe diseases by
upregulating protein expression with RNA-based medicines. Using
Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene
Output) approach, Stoke is developing antisense oligonucleotides
(ASOs) to selectively restore protein levels. Stoke’s first
compound, STK-001, is in clinical testing for the treatment of
Dravet syndrome, a severe and progressive genetic epilepsy. Dravet
syndrome is one of many diseases caused by a haploinsufficiency, in
which a loss of ~50% of normal protein levels leads to disease.
Stoke is pursuing the development of STK-002 for the treatment of
autosomal dominant optic atrophy (ADOA), the most common inherited
optic nerve disorder. Stoke’s initial focus is haploinsufficiencies
and diseases of the central nervous system and the eye, although
proof of concept has been demonstrated in other organs, tissues,
and systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/ or follow
Stoke on X @StokeTx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017613506/en/
Stoke Media & Investor Contacts: Dawn Kalmar Chief
Communications Officer dkalmar@stoketherapeutics.com
781-303-8302
Eric Rojas Vice President, Investor Relations
IR@stoketherapeutics.com 617-312-2754
Stoke Therapeutics (NASDAQ:STOK)
Gráfico Histórico do Ativo
De Out 2024 até Out 2024
Stoke Therapeutics (NASDAQ:STOK)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024